Get the Stockscreener App
52.70
8.68%
-5.01
After Hours:
52.69
-0.01
-0.02%
Arrowhead Pharmaceuticals Inc stock is traded at $52.70, with a volume of 2.64M.
It is down -8.68% in the last 24 hours and up +33.25% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$57.71
Open:
$56.39
24h Volume:
2.64M
Relative Volume:
1.12
Market Cap:
$7.29B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-37.91
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
+30.28%
1M Performance:
+33.25%
6M Performance:
+238.69%
1Y Performance:
+101.53%
1-Day Range:
$52.08
$56.67
1-Week Range:
$40.43
$59.15
52-Week Range:
$9.57
$59.15
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
52.70 | 7.84B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead (ARWR) Shares Drop Over 8% in Recent Trading - GuruFocus
Is Arrowhead Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Minimal Capital Trading - earlytimes.in
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead: Gains Make Mockery Of My Sell CallBut Jury May Still Be Out (Rating Upgrade) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (HDP1.F) stock price, news, quote and history - Yahoo Finance UK
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval - Finviz
Morgan Stanley Maintains Arrowhead Pharmaceuticals (ARWR) Equal-Weight Recommendation - MSN
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy - Yahoo Finance
Arrowhead Pharmaceuticals Hits Day High with 9.42% Surge in Stock Price - Markets Mojo
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - TipRanks
10 Big Names Feasting on Gains Ahead of Thanksgiving - Insider Monkey
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials - TipRanks
Arrowhead Pharmaceuticals Reports Record Revenue and FDA Approvals - StocksToTrade
Arrowhead’s Triumph: A New Dawn? - timothysykes.com
How (ARWR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026 - MSN
Arrowhead Pharmaceuticals: Hold Rating Amid Redemplo Launch and Financial Stability - TipRanks
Arrowhead (ARWR) Shares Surge Over 23% - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Arrowhead Pharmaceuticals Takes Significant Strides with FDA Approval Boosting Market Confidence - timothysykes.com
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Morgan Stanley Raises Price Target for ARWR to $48.00 | ARWR Sto - GuruFocus
Arrowhead (ARWR) Shares Surge by 9% - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $46.89 - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals : ARWR FQ4 2025 Script Final - MarketScreener
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals Q4 2025 sees stock surge - Investing.com Australia
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Achieves FDA Approval for REDEM - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... - Yahoo Finance
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q4 2025 Earnings Conference - 富途牛牛
Why Shares in Arcutis Biotherapeutics Surged Again This Week - AOL.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript - AOL.com
Arrowhead Pharmaceuticals (ARWR) Stock: Soars Following Strong Financial Performance and FDA Approval - parameter.io
Arrowhead Pharmaceuticals (ARWR) Surpasses Revenue Estimates wit - GuruFocus
Arrowhead Pharmaceuticals Fiscal-Year Loss Narrows, Revenue Rises - MarketScreener
Arrowhead (ARWR) Surpasses Revenue Expectations with FDA Approva - GuruFocus
Arrowhead reports FY25 EPS (1c), consensus (3c) - TipRanks
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - MarketScreener
[8-K] ARROWHEAD PHARMACEUTICALS, INC. Reports Material Event | ARWR SEC FilingForm 8-K - Stock Titan
Arrowhead Pharmaceuticals Hits New 52-Week High of $44.80 - Markets Mojo
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Arrowhead Pharmaceuticals FQ4 2025 Earnings Preview - MSN
ARWR Stock: Arrowhead Pharmaceuticals Hits New High as FDA Approval and Q4 Earnings Converge - ts2.tech
Arrowhead Pharmaceuticals (ARWR) Awaits FQ4 Earnings Amid Recent FDA Approval - GuruFocus
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):